Eli Lilly的阿尔茨海默氏病药物Kisunla在中国获得批准,目的是改善早期病人的治疗。 Eli Lilly's Alzheimer's drug, Kisunla, approved in China, aims to improve treatment for early-stage patients.

Eli Lilly的阿尔茨海默氏症药物Kisunla在中国被批准治疗早期症状性阿尔茨海默氏病, Eli Lilly's Alzheimer's drug, Kisunla, has been approved in China for treating early symptomatic Alzheimer's disease, marking its fourth major market approval after the US, Japan, and the UK. Kisunla是针对大脑中的氨基甲状腺斑块的,在临床试验中显示出巨大的效益,但也导致一些病人的大脑肿胀和出血。 Kisunla, which targets amyloid plaques in the brain, showed significant benefits in clinical trials but also caused brain swelling and bleeding in some patients. 该药物的批准旨在提高中国阿尔茨海默氏病患者的治疗标准。 The drug's approval aims to improve treatment standards for Alzheimer's patients in China.